Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar;7(2):97-113.
doi: 10.1177/1756285613512712.

4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review

Henrik Boye Jensen  1 , Mads Ravnborg  2 , Ulrik Dalgas  3 , Egon Stenager  4
Affiliations
Review

4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review

Henrik Boye Jensen et al. Ther Adv Neurol Disord. 2014 Mar.

Abstract

This systematic review summarizes the existing evidence on the effect of 4-aminopyridine (4-AP) as a symptomatic treatment of decreased walking capacity in patients with multiple sclerosis (MS) when administered as an immediate release compound and a slow release compound. It summarizes existing evidence on the basic mechanisms of 4-AP from experimental studies and evidence on the clinical use of the compound. A systematic literature search was conducted of the following databases: PubMed and EMBASE. Thirty-five studies were included in the review divided into 16 experimental studies, two clinical studies with paraclinical endpoints and 17 clinical studies with clinical endpoints. Animal studies show that 4-AP can improve impulse conduction through demyelinated lesions. In patients with MS this translates into improved walking speed and muscle strength of the lower extremities in a subset of patients at a level that is often of clinical relevance. Phase III trials demonstrate approximately 25% increase in walking speed in roughly 40% and improved muscle strength in the lower extremities. Furthermore, 4-AP might have an effect on other domains such as cognition, upper extremity function and bowel and bladder, but this warrants further investigation. Side effects are mainly mild to moderate, consisting primarily of paraesthesia, dizziness, nausea/vomiting, falls/balance disorders, insomnia, urinary tract infections and asthenia. Side effects are worse when administered intravenously and when administered as an immediate release compound. Serious adverse events are rarely seen in the marketed clinical dosages. In conclusion, 4-AP is easy and safe to use. Slow release 4-AP shows more robust clinical effects and a more beneficial side-effect profile than immediate release 4-AP.

Keywords: 4-aminopyridine; experimental studies; fampridine slow release; multiple sclerosis; translational medical research; treatment outcome.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: HBJ has received travel grants and teaching honoraries from Biogen Idec, Novartis, Almirall and Merck Serono and serves as an advisory board member for Novartis and Almirall. UD has received research support, travel grants and teaching honoraries from Biogen Idec, Merck Serono and Sanofi Aventis. UD further serves as PI for the ongoing Biogen-sponsored ACTIMS study. MR has received travel grants and consultancy honoraries from Biogen Idec, Genzyme, TEVA and Novartis and serves as an advisory board member for Biogen Idec. ES has received unrestricted research grants and travel support from Biogen Idec, Merck Serono and Bayer Schering and travel grants from Novartis.

Figures

Figure 1.
Figure 1.
Consort diagram of papers identified and included.
See this image and copyright information in PMC

References

    1. Bever C., Judge S. (2009) Sustained-release fampridine for multiple sclerosis. Expert Opin Investig Drugs 18: 1013–1024 - PubMed
    1. Bever C., Jr, Young D., Anderson P., Krumholz A., Conway K., Leslie J., et al. (1994) The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44: 1054–1059 - PubMed
    1. Blight A. (1989) Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 22: 47–52 - PubMed
    1. Blight A. (2011) Treatment of walking impairment in multiple sclerosis with dalfampridine. Ther Adv Neurol Disord 4: 99–109 - PMC - PubMed
    1. Blight A., Henney H., 3rd (2009) Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. Clin Ther 31: 328–335 - PubMed